(Q46155145)

20 December 2017

title

Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting (English)

1 reference

20 December 2017

major depressive disorder

main subject

1 reference

Ho-Jun Seo

1

1 reference

20 December 2017

Young-Eun Jung

2

1 reference

20 December 2017

Young Sup Woo

3

1 reference

20 December 2017

Tae-Youn Jun

4

1 reference

20 December 2017

Jeong-Ho Chae

5

1 reference

20 December 2017

Won-Myong Bahk

6

1 reference

20 December 2017

publication date

1 March 2009

1 reference

20 December 2017

published in

Human Psychopharmacology

1 reference

20 December 2017

volume

24

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

page(s)

135-143

1 reference

20 December 2017

Medical hazards of obesity

cites work

1 reference

Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors

21 January 2018

1 reference

7 January 2021

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

1 reference

7 January 2021

The unhealthy lifestyle of people with schizophrenia

1 reference

7 January 2021

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

7 January 2021

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

1 reference

7 January 2021

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

1 reference

7 January 2021

A Randomized, Double-Blind Study of Fluoxetine and Maprotiline in the Treatment of Major Depression

1 reference

7 January 2021

Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

1 reference

7 January 2021

Obesity as a correlate of outcome in patients with bipolar I disorder

1 reference

7 January 2021

Schizophrenia and weight management: a systematic review of interventions to control weight.

1 reference

7 January 2021

Glucose dysregulation and mirtazapine-induced weight gain

1 reference

7 January 2021

The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study

1 reference

7 January 2021

Social and economic consequences of overweight in adolescence and young adulthood

1 reference

7 January 2021

Antipsychotic-induced weight gain

1 reference

7 January 2021

A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder

1 reference

7 January 2021

Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors.

1 reference

7 January 2021

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

1 reference

7 January 2021

Therapeutic monitoring of new antipsychotic drugs

1 reference

7 January 2021

Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients

1 reference

7 January 2021

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

1 reference

7 January 2021

The role of serotonin in eating disorders

1 reference

7 January 2021

Medial hypothalamic nuclei mediate serotonin's inhibitory effect on feeding behavior.

1 reference

7 January 2021

Early predictors of substantial weight gain in bipolar patients treated with olanzapine

1 reference

7 January 2021

Weight Gain During Long-Term Treatment of Obsessive-Compulsive Disorder

1 reference

7 January 2021

A retrospective study of weight changes and the contributing factors in short term adult psychiatric inpatients

1 reference

7 January 2021

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

7 January 2021

Reversal of antipsychotic-associated weight gain.

1 reference

7 January 2021

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

7 January 2021

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder

1 reference

7 January 2021

Bodyweight change as an adverse effect of drug treatment. Mechanisms and management

1 reference

7 January 2021

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

1 reference

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

7 January 2021

A novel augmentation strategy for treating resistant major depression

1 reference

7 January 2021

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

1 reference

7 January 2021

Fluoxetine-maintained obese humans: effect on food intake and body weight

1 reference

7 January 2021

Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.1001

1 reference

20 December 2017

1 reference

20 December 2017